Standard BioTools Inc

In this Stage 4 decline, price has broken key support with a Support Failure pattern, and short-term and long-term trends remain down. Despite extreme oversold conditions, there are no signs of stabilization or institutional demand, with declining EMAs acting as resistance. Execution posture is bearish with the medium-term tradable side permitting a sell into rallies. Given unfavorable timing conditions for entering new bearish positions, execution should occur now on any relief bounce into EMAs or resistance areas.

• ↑Achieved $50M of $80M synergy goal by end-2024, boosting cost efficiency.
• ↑Consumables revenue grew 10% in Q4, driven by SomaScan kit sales.
• ↓Q1 2025 revenue declined 10% YoY to $40.8M, reflecting headwinds.